Mobile Menu - OpenMobile Menu - Closed

Hearing on “Examining Patient Access to Investigational Drugs,” Subcommittee on Health (October 3, 2017)

Date: 
Tuesday, October 3, 2017 - 10:30am
Location: 
2322 Rayburn House Office Building
Subcommittees: 

The Subcommittee on Health held a hearing on Tuesday, October 3, 2017, at 10:15 a.m. in 2322 Rayburn House Office Building. The hearing is entitled “Examining Patient Access to Investigational Drugs.” 

 

Livestream

 

Key Documents

Memorandum from Ranking Member Pallone to the Subcommittee on Health

Opening Statement of Ranking Member Pallone as prepared for delivery

Preliminary Transcript

 

Legislation

H.R. 1020, Compassionate Freedom of Choice Act of 2017, To allow the manufacture, importation, distribution, and sale of investigational drugs and devices intended for use by terminally ill patients who execute an informed consent document, and for other purposes. 

 

S. 204, Trickett Wendler, Frank Mongiello, Jordan McLinn, and Matthew Bellina Right to Try Act of 2017, To authorize the use of unapproved medical products by patients diagnosed with a terminal illness in accordance with State law, and for other purposes. 

 

Witnesses

Panel I:
Representative Andy Biggs (R-AZ)

Testimony


Representative Brian Fitzpatrick (R-PA)

Testimony


Panel II:
Scott Gottlieb, M.D.
Commissioner
U.S. Food and Drug Administration

Testimony


Panel III:
John Dicken
Director, Health Care
U.S. Government Accountability Office (GAO)

Testimony


Panel IV:
Naomi Lopez-Bauman
Director of Healthcare Policy
Goldwater Institute

Testimony


Lieutenant Commander Matthew Bellina
U.S. Navy (Retired)

Testimony


Kenneth I. Moch
President and CEO
Cognition Therapeutics, Inc.

Testimony


Alison Bateman-House, PhD, MPH, MA
Assistant Professor
Department of Population Health, New York University (NYU) Langone Health

Testimony


Ellen V. Sigal
Chairperson and Founder
Friends of Cancer Research

Testimony

 

Issues: